Can biomarkers identify women at increased stroke risk? The Women's Health Initiative Hormone Trials.

ABSTRACT:

Objective

The Women's Health Initiative hormone trials identified a 44% increase in ischemic stroke risk with combination estrogen plus progestin and a 39% increase with estrogen alone. We undertook a case-control biomarker study to elucidate underlying mechanisms, and to potentially identify women who would be at lower or higher risk for stroke with postmenopausal hormone therapy (HT).

Design

The hormone trials were randomized, double-blind, and placebo controlled.

Setting

The Women's Health Initiative trials were conducted at 40 clinical centers in the United States.

Participants

The trials enrolled 27,347 postmenopausal women, aged 50-79 y.

Interventions

We randomized 16,608 women with intact uterus to conjugated estrogens 0.625 mg with medroxyprogest

SUBMITTER: Kooperberg C 

PROVIDER: S-EPMC1891725 | biostudies-literature | 2007 Jun

REPOSITORIES: biostudies-literature